Retention rates of rufinamide in pediatric epilepsy patients with and without Lennox-Gastaut Syndrome.

@article{Kessler2015RetentionRO,
  title={Retention rates of rufinamide in pediatric epilepsy patients with and without Lennox-Gastaut Syndrome.},
  author={Sudha K. Kessler and Ann Lerene McCarthy and Avital Cnaan and Dennis J. Dlugos},
  journal={Epilepsy research},
  year={2015},
  volume={112},
  pages={18-26}
}
OBJECTIVE To evaluate the effectiveness of rufinamide (RFM) in patients with Lennox-Gastaut Syndrome (LGS) compared to those with other epilepsy syndromes using time to treatment failure (retention rate) as the outcome measure. METHODS In this retrospective cohort study, characteristics and outcomes of all patients receiving RFM in 2009 and 2010 were recorded. The primary outcome measure was RFM failure, defined as discontinuation of RFM or initiation of an additional antiepileptic therapy… CONTINUE READING